We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: PNH
MedXY News
EnglishTag

PNH

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Clonal Hematopoiesis Dynamics in Aplastic Anemia Patients Undergoing Immunosuppressive Therapy: Insights and Clinical Implications
Hematology-OncologyPNHaplastic anemia

Clonal Hematopoiesis Dynamics in Aplastic Anemia Patients Undergoing Immunosuppressive Therapy: Insights and Clinical Implications

By MedXY|Sep 11, 2026

Longitudinal analysis of 371 aplastic anemia patients reveals distinct patterns of clonal hematopoiesis under immunosuppressive therapy, highlighting variable mutation dynamics, cytogenetic changes, and progression risks.

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies
Clinical Updatesclinical trials
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
iptacopan

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies

By MedXY|Jan 19, 2026

This review synthesizes clinical trial evidence for Iptacopan, focusing on its transformative role in treating PNH through proximal complement inhibition and its emerging efficacy in IgA nephropathy and C3 glomerulopathy.

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Haemoglobinuria: 48-Week Outcomes from APPLY-PNH and APPOINT-PNH Phase 3 Trials
Clinical Updatescomplement inhibitoriptacopan

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Haemoglobinuria: 48-Week Outcomes from APPLY-PNH and APPOINT-PNH Phase 3 Trials

By MedXY|Oct 1, 2025

Oral iptacopan provides sustained haemolysis control and improved haemoglobin in PNH patients over 48 weeks, with a favorable safety profile, supporting its role as a new therapeutic option.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities